Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI) Normalized Income after Taxes data is not available for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Normalized Income after Taxes |
-- |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$1.51M |
|
$8.50M |
|
$10.33M |
|
$11.84M |
|
$2.12M |
|
$0.29M |
|
$1.86M |
|
$3.98M |
|
$2.23M |
|
$7.86M |
|
$7.86M |
|
1.51M |
|
| Cash Flow Statement Financials | |
$-2.58M |
|
$-0.01M |
|
$1.58M |
|
$2.10M |
|
$1.13M |
|
$-0.96M |
|
$0.27M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|